Log in to save to my catalogue

Individualized atomoxetine response and tolerability in children with ADHD receiving different dosag...

Individualized atomoxetine response and tolerability in children with ADHD receiving different dosag...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6b1769d95e25434d89723d5330a28112

Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together

About this item

Full title

Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together

Publisher

London: Nature Publishing Group UK

Journal title

Translational psychiatry, 2024-03, Vol.14 (1), p.151-151, Article 151

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Integrating
CYP2D6
genotyping and therapeutic drug monitoring (TDM) is crucial for guiding individualized atomoxetine therapy in children with attention-deficit/hyperactivity disorder (ADHD). The aim of this retrospective study was (1) to investigate the link between the efficacy and tolerability of atomoxetine in children with ADHD and plasm...

Alternative Titles

Full title

Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_6b1769d95e25434d89723d5330a28112

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6b1769d95e25434d89723d5330a28112

Other Identifiers

ISSN

2158-3188

E-ISSN

2158-3188

DOI

10.1038/s41398-024-02859-2

How to access this item